Norwegia - Norwegia - Statens legemiddelverk

orifarm as - sildenafilsitrat - tablett, filmdrasjert - 25 mg

Norwegia - Norwegia - Statens legemiddelverk

farmagon - sildenafilsitrat - tablett, filmdrasjert - 100 mg

Norwegia - Norwegia - Statens legemiddelverk

farmagon - sildenafilsitrat - tablett, filmdrasjert - 50 mg

Norwegia - Norwegia - Statens legemiddelverk

2care4 aps - finasterid - tablett, filmdrasjert - 5 mg

Norwegia - Norwegia - Statens legemiddelverk

orifarm as - tadalafil - tablett, filmdrasjert - 5 mg

Norwegia - Norwegia - Statens legemiddelverk

orifarm as - tadalafil - tablett, filmdrasjert - 10 mg

Norwegia - Norwegia - Statens legemiddelverk

orifarm as - tadalafil - tablett, filmdrasjert - 20 mg

Norwegia - Norwegia - Statens legemiddelverk

farmagon - tadalafil - tablett, filmdrasjert - 20 mg

Norwegia - Norwegia - Statens legemiddelverk

2care4 aps - tadalafil - tablett, filmdrasjert - 20 mg

Uni Eropa - Norwegia - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - legemidler for obstruktive sykdommer i luftveiene, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).